Shares of Merck & Co. Inc. MRK dropped 0.58% to $114.96 Tuesday, on what proved to be an all-around positive trading session ...

Shares of Merck & Co. Inc. MRK shed 1.31% to $115.63 Monday, on what proved to be an all-around great trading session for the ...

(RTTNews) - Drug major Merck & Co., Inc. (MRK) announced Wednesday that the U.S. Food and Drug Administration has approved its anti-PD-1 therapy KEYTRUDA (pembrolizumab), in combination with ...

Charlie CY Yang, an analyst from Bank of America Securities, maintained the Buy rating on Merck & Company (MRK – Research Report). The associated price target is $140.00. Charlie CY Yang has ...

The Committee for Medicinal Products for Human Use recommends marketing approval for Merck's Keytruda for treating two types of gynecologic cancers. The FDA approves MRK's Keytruda for first-line ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In iOS 18, Apple has made a significant enhancement to the Notes app, introducing a built-in audio recording feature that streamlines the process of capturing and transcribing voice notes.

Non-muscle-invasive bladder cancer (NMIBC) is a type of bladder cancer where the tumor remains confined to the bladder's ...

During an R&D update yesterday Merck said it is hoping to claim eight new cardiovascular therapy approvals between now and 2030, for diseases like atherosclerosis, heart failure, pulmonary ...

AstraZeneca and Merck & Co's Lynparza has been the undisputed market leader in the PARP inhibitor category for some years, but would-be competitors continue to chip away at its market share.

Analysts see big upside for these undervalued health care stocks.

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...